Does insurance cover GLP-1 medications?

Coverage varies widely. Many commercial insurance plans now cover at least one GLP-1 medication for weight loss, but coverage is not universal. Patients typically need to meet specific criteria (BMI, comorbidities) and complete a prior authorization process. As of 2026, Medicare is expanding coverage for obesity medications, which is a significant shift.

How do I get prior authorization approved for GLP-1?

Prior authorization approval typically requires: documentation of BMI (usually 30+ or 27+ with comorbidities), evidence of a previous weight loss attempt (diet/exercise), supporting lab work, and a clinician's statement of medical necessity. Working with a provider experienced in insurer navigation, such as Ro or FORM Health , can significantly improve approval rates.

What if my insurance denies GLP-1 coverage?

If denied, you have the right to appeal. First-level appeals succeed approximately 30 to 50% of the time with proper documentation. Your clinician can submit a letter of medical necessity, additional supporting documentation, and references to clinical guidelines. If the first appeal fails, most plans allow a second-level appeal and an external review. Some providers assist with the appeal process as part of their service.

Are there manufacturer savings cards for GLP-1?

Yes. Novo Nordisk and Eli Lilly both offer savings programs that can reduce out-of-pocket costs for commercially insured patients. These programs typically cover a portion of the copay and can reduce costs to $25 to $150 per month for eligible patients. However, savings cards usually do not apply to government insurance (Medicare, Medicaid) and have maximum benefit limits.

Will Medicare cover GLP-1 for weight loss?

The expected July 2026 Medicare coverage expansion is projected to extend obesity medication coverage to Medicare beneficiaries, which would be a historic shift. Specific implementation details, formulary placement, and prior authorization requirements are still being finalized. Patients on Medicare should monitor updates from CMS and discuss options with their clinician.

Guide

How to Get GLP-1 Covered by Insurance (2026)

A practical guide to getting GLP-1 medications covered by insurance, including prior authorization strategies, appeal processes, manufacturer savings cards, and the 2026 Medicare coverage expansion.

Updated April 2026Editorially ReviewedEditorial Independence

The insurance landscape for GLP-1 medications in 2026

Getting GLP-1 medications covered by insurance has historically been one of the biggest barriers to treatment. In 2026, the landscape is shifting. More commercial insurers are covering weight loss medications, Medicare coverage is expected to expand in July 2026, and some state Medicaid programs are adding coverage. But the process remains complicated, inconsistent, and frequently frustrating for patients. Understanding how the system works gives patients a meaningful advantage in accessing treatment at a manageable cost.

The core challenge is that insurance coverage for obesity medications has lagged behind the clinical evidence. Even as GLP-1 drugs have demonstrated 15 to 22% body weight loss with significant reductions in cardiovascular risk, many payers have been slow to classify obesity treatment as essential. That is changing, but unevenly, which is why patients need to navigate the system actively rather than assuming their plan will cover treatment automatically.

ClearlyMeds is an independent editorial team. Revenue never influences our rankings, and every guide is written to help readers understand tradeoffs in plain English rather than push a single provider.

Commercial coverage is expanding but varies by plan
Medicare expansion expected July 2026
Prior authorization is almost always required
Provider choice significantly affects approval success

Prior authorization: how to get approved

Prior authorization is the process by which an insurer reviews and approves coverage for a medication before the pharmacy will fill it at the covered price. For GLP-1 medications, prior authorization is standard. The typical criteria include: BMI of 30 or higher (or 27+ with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), documentation of a previous weight loss attempt through diet and exercise (usually within the past 12 months), relevant lab work (A1C, lipid panel, metabolic panel), and a clinician's statement of medical necessity.

The quality of the prior authorization submission matters enormously. A well-documented request that includes all required elements, references current clinical guidelines (such as the AGA or Endocrine Society obesity treatment guidelines), and clearly states medical necessity is far more likely to be approved on the first attempt. Providers with experience in insurer navigation, like Ro, FORM Health, and Calibrate, often have dedicated teams or processes for handling prior authorizations.

Patients can help by gathering their documentation in advance: recent lab results, records of previous weight loss attempts, a list of weight-related health conditions, and current medications. The more complete the initial submission, the faster the approval process.

What to do when you are denied

Insurance denials for GLP-1 medications are common but not final. Patients have the right to appeal, and appeals succeed more often than most people expect. First-level appeals are approved approximately 30 to 50% of the time when accompanied by strong documentation and a clinician's letter of medical necessity.

The appeal process typically works in stages: First-level appeal involves submitting additional documentation and a letter from your prescribing clinician explaining why the medication is medically necessary for your specific situation. Second-level appeal may involve a peer-to-peer review, where your clinician speaks directly with the insurer's medical reviewer. External review is available in most states if internal appeals are exhausted, involving an independent reviewer not employed by the insurance company.

Key tips for successful appeals: reference published clinical guidelines, include specific health data (not just BMI, but blood pressure, A1C, sleep apnea diagnosis, etc.), document that alternative treatments were tried and insufficient, and be persistent. Many patients give up after the first denial, which is exactly what insurers count on.

Manufacturer savings programs and other cost reduction

Both Novo Nordisk (maker of Wegovy/Ozempic) and Eli Lilly (maker of Mounjaro/Zepbound) offer patient savings programs for commercially insured patients. These programs can reduce copays to $25 to $150 per month depending on the specific program and the patient's insurance. Savings programs typically require commercial insurance (not government programs like Medicare or Medicaid) and have annual maximum benefit caps.

Other cost reduction strategies include: asking your clinician about step therapy (starting with a less expensive medication to satisfy insurer requirements before moving to the preferred drug), checking whether a different GLP-1 medication has better formulary placement on your specific plan, exploring pharmacy options (mail-order pharmacies sometimes offer better pricing), and using GoodRx or similar discount cards as a backup when insurance coverage gaps occur.

For patients without usable insurance coverage, cash-pay telehealth programs or compounded medication pathways may be more practical. But patients should exhaust insurance options first, because the long-term cost savings of covered treatment are substantial.

The 2026 Medicare expansion and what it means

The expected July 2026 Medicare coverage expansion for obesity medications represents the most significant policy change in this space in decades. If implemented as projected, it would provide millions of Medicare beneficiaries with access to GLP-1 medications for weight loss, a category that Medicare has historically excluded from coverage.

Patients on Medicare should understand that even with expanded coverage, prior authorization, formulary restrictions, and cost-sharing will likely apply. The implementation details are still being finalized, and the rollout may be uneven. Working with a provider experienced in Medicare navigation will be important during the transition period.

For patients under 65 with commercial insurance, the Medicare expansion may also have indirect benefits by normalizing obesity medication coverage across the insurance industry. As Medicare demonstrates willingness to cover these medications, commercial payers may face increased pressure to expand their own coverage.

This guide is educational and not a substitute for personal medical advice. Eligibility, contraindications, and monitoring needs differ across individuals, which is why treatment decisions should be reviewed with a licensed clinician.